Proteins and Peptides

18 Feb 2019 Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium
14 Feb 2019 DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
13 Feb 2019 Clinigen to acquire US rights to Proleukin
13 Feb 2019 BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2
12 Feb 2019 Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism
07 Feb 2019 Medicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of MDNA55
06 Feb 2019 Orphan Technologies Announces First Patients Treated in Phase 1/2 Trial of OT-58 in Homocystinuria
06 Feb 2019 BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites
06 Feb 2019 Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109
03 Feb 2019 Evolus Receives FDA Approval for Jeuveau™ prabotulinumtoxinA-xvfs for Injection
23 Jan 2019 Oramed Initiates Phase I Oral GLP-1 Study Under IND
23 Jan 2019 Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
17 Jan 2019 Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 2019
12 Jan 2019 Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019
10 Jan 2019 Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
07 Jan 2019 Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America
03 Jan 2019 First-in-human Study of Precision Immune Stimulant PIN-2 Demonstrated Pharmacologic Activity and Safety in Patients with Advanced Solid Tumors
27 Dec 2018 Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia
22 Dec 2018 FDA approves longer-acting calaspargase pegol-mknl for ALL
20 Dec 2018 AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
20 Dec 2018 Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
20 Dec 2018 Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes
19 Dec 2018 PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi™ (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
19 Dec 2018 Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial Dec
17 Dec 2018 Cerenis Therapeutics: Final Results of TARGET PHASE II Study Demonstrate the Ability of CER-001, an HDL Mimetic, to Target Tumor in Patients with Esophageal Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top